A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis

Systemic Sclerosis Clinical Trial

Official title:

A Phase II, Randomized, Multi-center, Placebo-controlled, Double-blind Study to Investigate the Safety of GS-248, and Efficacy on Raynaud's Phenomenon (RP) and Peripheral Vascular Blood Flow, in Subjects With Systemic Sclerosis (SSc)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04744207
• Other study ID #: GS-2001
• Status: Completed
• Phase: Phase 2
• Start date: December 29, 2020
• Est. completion date: June 15, 2022

Study information

• Verified date: August 2022
• Source: Gesynta Pharma AB
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to determine the safety, and evaluate the efficacy of GS-248 versus placebo on Raynaud's Phenomenon (RP) in subjects with Systemic Sclerosis (SSc).

Description:

The primary objective of this study is to determine the safety, and evaluate the efficacy of GS-248 versus placebo on Raynaud's Phenomenon (RP) in subjects with Systemic Sclerosis (SSc).

This is a randomized, double-blind, placebo-controlled study conducted in multiple sites in 4 countries in Europe. Approximately 80 subjects will be randomized in a 1:1 allocation to receive either GS-248 (120 mg) or placebo once daily. The study will comprise an enrolment period, a treatment period, and a follow-up period, with a total of 5 study visits over approximately 10 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 69
• Est. completion date: June 15, 2022
• Est. primary completion date: June 15, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Subjects must provide signed and dated written informed consent before the conduct of any study-specific procedures.

• Male and female subjects aged 18-75 years inclusive.

• Systemic Sclerosis diagnosed according to European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) criteria (van den Hoogen F et al. 2013). Subjects with signs of other autoimmune diseases (e.g. Sjögren's syndrome, myositis, rheumatoid arthritis) could be included if SSc is the dominating phenotype.

• Raynaud attacks typically =7 times per week during the last 4 weeks prior to screening despite background medication (only allowed vasodilatory therapy is calcium channel blockers or PDE-5 inhibitors).

• Women of childbearing potential must be using a highly effective method of contraception to avoid pregnancy throughout the study and for 4 weeks after the last dose of Investigational Medicinal Product in such manner that the risk of pregnancy is minimised.

• Women must not be pregnant or breastfeeding.

• Male subjects to agree to use condom in combination with use of contraceptive methods with a failure rate of <1% to prevent pregnancy and drug exposure of a partner, and refrain from donating sperm from the first date of dosing until 3 months after last dosing of the IMP.

• Ability of subjects to participate fully in all aspects of this clinical trial.

Exclusion Criteria:

• Systemic Sclerosis disease duration of greater than 120 months from first non-Raynaud manifestation

• Current smokers or stopped smoking <3 months prior to Visit 1.

• Dose-change or initiation of vasodilating substances (calcium blockers or PDE-5 inhibitors) within 4 weeks prior to Visit 1.

• Use of iloprost or other intravenous (iv) or po prostacyclin receptor agonist within 4 weeks prior to Visit 1.

• Ongoing treatment with immunosuppressive therapies (other than mycophenolate) including, but not restricted to; cyclophosphamide, azathioprine, methotrexate, or cyclosporine, or use of those medications within 4 weeks of trial entry.

• Use of systemic corticosteroids during 4 weeks before screening and during the course of the study.

• Concurrent serious medical condition, with special attention to cardiovascular conditions, which in the opinion of the Investigator makes the subject not suitable for this study.

• Prolonged QTcF interval defined as a mean QTcF >450 msec.

• Creatinine clearance <50 mL/min (determined by Cockcroft-Gault equation) at Screening.

• Active digital ulcer (DU) within 4 weeks prior to Visit 1.

• Clinically meaningful laboratory abnormalities at Screening (Visit 1), as determined and documented by the Investigator.

Related Conditions & MeSH terms

• Raynaud Disease
• Scleroderma, Diffuse
• Scleroderma, Systemic
• Sclerosis
• Systemic Sclerosis

Intervention

Drug:
• GS-248
120 mg, capsule, once daily for 4 weeks
• Placebo
capsule, once daily for 4 weeks

Locations

Country	Name	City	State
Belgium	Investigator site	Gent
Netherlands	Investigator Site	Nijmegen
Poland	Investigator site	Gdansk
Poland	Investigator Site	Kraków
Poland	Investigator site	Lublin
United Kingdom	Investigator site	Bath
United Kingdom	Investigator site	Cambridge
United Kingdom	Investigator Site	Dundee
United Kingdom	Investigator site	Leeds
United Kingdom	Investigator Site	Liverpool
United Kingdom	Investigator Site	London
United Kingdom	Investigator site	Manchester

Sponsors (2)

Lead Sponsor	Collaborator
Gesynta Pharma AB	Ergomed

Countries where clinical trial is conducted

Belgium,  Netherlands,  Poland,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean change from baseline to week 4 in the number of Raynaud attacks per week.	Patient reported number of Raynaud's attacks per day as registered in electronic diary.	Daily from Day -7 to Day 28
Primary	Mean change from baseline to week 4 in the Raynaud's Condition Score.	Patient reported Raynaud's Condition Score each day as registered in electronic diary.	Daily from Day -7 to Day 28
Primary	Mean change from baseline to week 4 in the cumulative duration of Raynaud attacks.	Patient reported duration of Raynaud's attacks per day as registered in electronic diary.	Daily from Day -7 to Day 28
Primary	Mean change from baseline to week 4 in pain experienced during Raynaud attacks.	Patient reported pain of each Raynaud attack using Numeric Rating Scale as registered in electronic diary.	Daily from Day -7 to Day 28
Primary	Number of treatment emergent adverse events	Frequency, severity and seriousness of treatment emergent adverse events	Daily from Day 1 to Day 42-49
Secondary	Mean change in peripheral blood flow in fingers	Peripheral blood flow will be measured with thermography assessments before and after cold challenge.	Day 1 at pre-dose and 2 hours post dose and Day 28 at pre dose